License, Commercialization and Supply Agreements (Details 3) (USD $)	12 Months Ended			0 Months Ended	12 Months Ended	0 Months Ended		0 Months Ended			12 Months Ended	0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013 STENDRA/SPEDRA	Dec. 31, 2013 License and commercialization agreement STENDRA/SPEDRA Sanofi	Dec. 31, 2013 License and commercialization agreement STENDRA/SPEDRA Sanofi	Dec. 11, 2013 License and commercialization agreement Manufacturing milestone payments Maximum	Dec. 31, 2013 License and commercialization agreement Manufacturing milestone payments Sanofi	Dec. 11, 2013 License and commercialization agreement Regulatory milestone payments Maximum	Dec. 11, 2013 License and commercialization agreement Milestone based on net sales target met Maximum	Jul. 31, 2013 Commercial Supply Agreement Sanofi Chimie	Dec. 31, 2013 Commercial Supply Agreement STENDRA/SPEDRA Sanofi	Nov. 18, 2013 Manufacturing and Supply Agreement for Avanafil Tablets Sanofi Winthrop Industrie
License, Commercialization and Supply Agreements
Upfront payments received				$ 5,000,000
Proceeds from payments for manufacturing milestone				1,500,000
Amount of regulatory milestone payment which the entity is eligible to receive						3,500,000		6,000,000	45,000,000
License revenue	55,838,000				4,400,000
Revenue recognized from initial product delivered	25,244,000	2,012,000	1,526,000								446,000
Current deferred revenue	$ 17,255,000	$ 1,150,000					$ 1,600,000
Initial term										5 years		5 years
Additional period of auto-renewal										2 years		2 years